Related Experiment Video
Updated: Dec 22, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
LDL-Cholesterol-Lowering Therapy
Angela Pirillo1,2, Giuseppe D Norata3,1, Alberico L Catapano4,5
1Center for the Study of Atherosclerosis, E. Bassini Hospital, Milan, Italy.
Insights
Elevated LDL-C causes cardiovascular disease, making LDL-C reduction key for prevention. New drugs offer alternatives or complements to statins for managing residual cardiovascular risk.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- Established link between high low-density lipoprotein cholesterol (LDL-C) and cardiovascular disease (CVD).
- Statins are primary therapy for lowering LDL-C, but residual CVD risk persists.
- Need for alternative or adjunctive lipid-lowering therapies due to statin intolerance and residual risk.
Purpose of the Study:
- To review the role of LDL-C in cardiovascular disease.
- To discuss the limitations of statin therapy.
- To explore novel lipid-lowering drugs with different mechanisms or targets.
Main Methods:
- Review of experimental and clinical studies on LDL-C and CVD.
- Analysis of therapeutic strategies for lipid management.
- Examination of recently approved lipid-lowering agents.
Main Results:
- Confirmation of LDL-C as a major cardiovascular risk factor.
- Identification of residual lipid-related risk despite statin use.
- Emergence of new drugs targeting different lipoproteins or pathways.
Conclusions:
- Reducing LDL-C remains a critical goal in cardiovascular disease prevention.
- New pharmacological options are available for patients needing alternatives or additions to statins.
- These advancements address unmet needs in managing hyperlipidemia and reducing cardiovascular risk.
Abstract:
The causal relation between elevated levels of LDL-C and cardiovascular disease has been largely established by experimental and clinical studies. Thus, the reduction of LDL-C levels is a major target for the prevention of cardiovascular disease. In the last decades, statins have been used as the main therapeutic approach to lower plasma cholesterol levels; however, the presence of residual lipid-related cardiovascular risk despite maximal statin therapy raised the need to develop additional lipid-lowering drugs to be used in combination with or in alternative to statins in patients intolerant to the treatment. Several new drugs have been approved which have mechanisms of action different from statins or impact on different lipoprotein classes.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures
Lipids: Dietary Sources and Requirements
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

